KRAS Antibody (3B10-2F2) - Azide and BSA Free

Western Blot: KRAS Antibody (3B10-2F2) [H00003845-M01] - Western blot analysis of KRAS expression in lysates from human lung cancer cell lines: H23, H358, A549, and H441. Image from verified customer review.

Western Blot: KRAS Antibody (3B10-2F2) [H00003845-M01] - Western Blot analysis of KRAS expression in transfected 293T cell line by KRAS monoclonal antibody (M01), clone 3B10-2F2.Lane 1: KRAS transfected lysate(21 KDa).Lane 2: Non-transfected lysate.

Immunocytochemistry/Immunofluorescence: KRAS Antibody (3B10-2F2) [H00003845-M01] - Analysis of monoclonal antibody to KRAS on HeLa cell. Antibody concentration 10 ug/ml.

Western Blot: KRAS Antibody (3B10-2F2) [H00003845-M01] - KRAS monoclonal antibody (M01), clone 3B10-2F2 Analysis of KRAS expression in HeLa.

Western Blot: KRAS Antibody (3B10-2F2) [H00003845-M01] - miRNA-768-3p specifically targets K-ras. Effect of miRNA inhibitors that were reduced by co-culture on the level of pan-RAS, phospho-B-Raf and CD44 and pan-Akt by western blotting. Also shown is the effect of different miRNA inhibitors on the level of K-ras in H520 cells by western blot. Cropped blots are shown and were run under the same experimental conditions. Image collected and cropped by CiteAb from the following publication (//www.nature.com/articles/srep02392), licensed under a CC-BY license.

ELISA: KRAS Antibody (3B10-2F2) [H00003845-M01] - Detection limit for recombinant GST tagged KRAS is approximately 1ng/ml as a capture antibody.

• Reactivity: Hu, Mu
• Applications: WB, ELISA, ICC/IF, IP
• Clone: 3B10-2F2
• Clonality: Monoclonal
• Host: Mouse
• Conjugate: Unconjugated
• Format: Azide and BSA Free

KRAS Antibody (3B10-2F2) - Azide and BSA Free Summary

• Description: Quality control test: Antibody Reactive Against Recombinant Protein.
• Immunogen: KRAS (AAH13572, 1 a.a. ~ 188 a.a) full-length recombinant protein with GST tag. MW of the GST tag alone is 26 KDa. MTEYKLVVVGAGGVGKSALTIQLIQNHFVDEYDPTIEDSYRKQVVIDGETCLLDILDTAGHEEYSAMRDQYMRTGEGFLCVFAINNTKSFEDIHHYREQIKRVKDSEDVPMVLVGNKCDLPSRTVDTKQAQDLARSYGIPFIETSAKTRQGVDDAFYTLVREIRKHKEKMSKDGKKKKKKSKTKCVIM
• Specificity: KRAS - v-Ki-ras2 Kirsten rat sarcoma viral oncogene homolog
• Isotype: IgG1 Kappa
• Clonality: Monoclonal
• Host: Mouse
• Gene: KRAS
• Purity: IgG purified

Applications/Dilutions

• Dilutions:
  • ELISA
  • Immunocytochemistry/ Immunofluorescence 1:10-1:500
  • Immunoprecipitation 1:10-1:500
  • Western Blot
• Application Notes: Antibody reactivity against cell lysate and recombinant protein for WB. It has been used for IF and ELISA. IP usage was reported in scientific literature. Customer feedback on frozen sections has been negative.

Packaging, Storage & Formulations

• Storage: Aliquot and store at -20C or -80C. Avoid freeze-thaw cycles.
• Buffer: In 1x PBS, pH 7.4
• Preservative: No Preservative
• Purity: IgG purified

Notes

This product is produced by and distributed for Abnova, a company based in Taiwan.

Alternate Names for KRAS Antibody (3B10-2F2) - Azide and BSA Free

• cellular c-Ki-ras2 proto-oncogene
• c-Ki-ras
• C-K-RAS
• GTPase KRas
• KI-RAS
• Kirsten rat sarcoma-2 viral (v-Ki-ras2) oncogene homolog
• K-Ras 2
• K-ras p21 protein
• KRAS1
• K-RAS2A
• K-RAS2B
• KRAS2NS3
• K-RAS4A
• K-RAS4B
• NS
• oncogene KRAS2
• PR310 c-K-ras oncogene
• RASK2c-Kirsten-ras protein
• transforming protein p21
• v-Ki-ras2 Kirsten rat sarcoma 2 viral oncogene homolog
• v-Ki-ras2 Kirsten rat sarcoma viral oncogene homolog

Background

This gene, a Kirsten ras oncogene homolog from the mammalian ras gene family, encodes a protein that is a member of the small GTPase superfamily. A single amino acid substitution is responsible for an activating mutation. The transforming protein that results is implicated in various malignancies, including lung adenocarcinoma, mucinous adenoma, ductal carcinoma of the pancreas and colorectal carcinoma. Alternative splicing leads to variants encoding two isoforms that differ in the C-terminal region.

Limitations

This product is for research use only and is not approved for use in humans or in clinical diagnosis. Primary Antibodies are guaranteed for 1 year from date of receipt.

Publications for KRAS Antibody (H00003845-M01)(18)

Publications using H00003845-M01

• Chapeau EA, Sansregret L, Galli GG et Al. Direct and selective pharmacological disruption of the YAP-TEAD interface by IAG933 inhibits Hippo-dependent and RAS-MAPK-altered cancers Nat Cancer 2024-04-02 [PMID: 38565920]
• Alexandra A, Ryan L, Chun-Hao H et al. Endogenous spacing enables co-processing of microRNAs and efficient combinatorial RNAi. Cell Rep Methods. 2022-06-21 [PMID: 35880017]
• Anke B, Sheryll E, Daniel G et al. EndoBind detects endogenous protein-protein interactions in real time. Commun Biol. 2021-09-15 [PMID: 34526658]
• Seon-Hyeong L, Yoon J, Joon K et al. The Combination of Loss of ALDH1L1 Function and Phenformin Treatment Decreases Tumor Growth in KRAS-Driven Lung Cancer. Cancers (Basel). 2020-05-28 [PMID: 32481524]
• Almas Y, Wai L, Victor L et al. Grifolin, neogrifolin and confluentin from the terricolous polypore Albatrellus flettii suppress KRAS expression in human colon cancer cells. PLoS One. 2020-05-05 [PMID: 32369483]
• Sherekar M, Han SW, Ghirlando R et al. Biochemical and structural analyses reveal that the tumor suppressor neurofibromin (NF1) forms a high-affinity dimer J. Biol. Chem. 2020-01-24 [PMID: 31836666] (WB, Human)
• Cao S, Chung S, Kim S et al. K-Ras G-domain binding with signaling lipid phosphatidylinositol (4,5)-phosphate (PIP2): membrane association, protein orientation, and function. J Biol Chem. 2019-02-21 [PMID: 30792310]
• Ahmed TA, Adamopoulos C, Karoulia Z et al. SHP2 Drives Adaptive Resistance to ERK Signaling Inhibition in Molecularly Defined Subsets of ERK-Dependent Tumors. Cell Rep 2019-01-02 [PMID: 30605687] (WB, Human)
• Garcia-Berrocoso T, Llombart V, Colas-Campas L et al. Single Cell Immuno-laser Microdissection Coupled to Label-free Proteomics to Reveal the Proteotypes of Human Brain Cells After Ischemia Mol. Cell Proteomics. 2017-11-13 [PMID: 29133510] (ICC/IF, Human)
• Kuracha MR, Thomas P, Loggie BW, Govindarajan V et al. Bilateral blockade of MEK- and PI3K-mediated pathways downstream of mutant KRAS as a treatment approach for peritoneal mucinous malignancies. PLoS One 2017-06-22 [PMID: 28640835]
• Forzati F, De Martino M, Esposito F et al. miR-155 is positively regulated by CBX7 in mouse embryonic fibroblasts and colon carcinomas, and targets the KRAS oncogene. BMC Cancer 2017-03-04 [PMID: 28259135]
• Madureira PA, Bharadwaj AG, Bydoun M et al. Cell surface protease activation during RAS transformation: Critical role of the plasminogen receptor, S100A10. Oncotarget 2016-06-24 [PMID: 27351226]
• Ambrosini G, Khanin R, Carvajal RD et al. Overexpression of DDX43 mediates MEK-Inhibitor Resistance through RAS up-regulation in Uveal Melanoma Cells. Mol Cancer Ther 2014-06-04 [PMID: 24899684]
• King S, Bray S, Galbraith S et al. Evidence for aldosterone-dependent growth of renal cell carcinoma. Int J Exp Pathol. 2014-05-07 [PMID: 24802662]
• Subramani A, Alsidawi S, Jagannathan S et al. The brain microenvironment negatively regulates miRNA-768-3p to promote K-ras expression and lung cancer metastasis. Sci Rep. 2013-08-09 [PMID: 23928793] (WB, Human)
• Valtorta E, Misale S, Sartore-Bianchi A et al. KRAS gene amplification in colorectal cancer and impact on response to EGFR-targeted therapy. Int J Cancer. 2013-01-21 [PMID: 23404247]
• Hsu SP, Lee WS et al. Progesterone receptor activation of extranuclear signaling pathways in regulating p53 expression in vascular endothelial cells. Mol Endocrinol 2011-03-01 [PMID: 21239614] (WB, IP, Human)
• Fuentes-Calvo I, Blazquez-Medela AM, Santos E et al. Analysis of k-ras nuclear expression in fibroblasts and mesangial cells. PLoS One 5(1):e8703. 2010-01-14 [PMID: 20090846]

Review for KRAS Antibody (H00003845-M01) (1)

Average Rating: 4

(Based on 1 review)

We have 1 review tested in 1 species: Human.

reviewed by: Anon ymous WB Human 03/14/2014

Summary

• Application: Western Blot
• Sample Tested: Whole cell lysate from the following human lung cancer lines: H23, H358, A549, H441.
• Species: Human

Bioinformatics

• Gene Symbol: KRAS
• Entrez:
  • 3845(Human)
• OMIM:
  • 109800(Human)
• Uniprot:
  • AAH13572(Human)